Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 611 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR How the National Cancer Act Has Made a Difference in Cancer... February 18, 2021 New on NCI’s Website for July 2023 – Researcher/Trainee Special Edition July 21, 2023 Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare... April 24, 2023 Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in... May 10, 2024 Load more HOT NEWS Looking to Help Rebuild Strength After Breast Cancer Treatment? Soccer May... Mom Discovers She Has Breast Cancer After Weaning Twin Boys, Says... No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... ESMO Calls for Cancer Care Safeguards in the EU’s Health Crisis...
